文献速递肿瘤 PET/CT骨显像与常规 SPECT

多发性骨髓瘤PET显像再定义:FDG与氟胆碱PET/CT对比研究

PET in myeloma redefined: a comparative imaging study with FDG and fluorocholine PET/CT.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-10-23

单中心回顾性研究纳入35例多发性骨髓瘤患者,四周内行FDG与氟胆碱双示踪剂PET/CT。氟胆碱检出91%患者活动性疾病,灵敏度94.1%,均优于FDG的49%和50.0%,且与骨髓浆细胞浸润及血红蛋白、白蛋白相关,提示其更可靠反映疾病负荷。

要点

  • 氟胆碱PET/CT检出率91%、灵敏度94.1%,FDG分别为49%、50.0%。
  • 两者骨髓Deauville评分相似,但氟胆碱高代谢灶评分显著更高。
  • 氟胆碱摄取与浆细胞浸润、血红蛋白、白蛋白相关,FDG无一致关联。

核心结论

  • 氟胆碱PET/CT在多发性骨髓瘤中诊断性能优于FDG,尤以红骨髓丰富区域明显,更可靠反映疾病负荷并与实验室指标一致。

研究设计与样本

  • 单中心回顾性研究,35例成年多发性骨髓瘤患者四周内完成FDG与氟胆碱双示踪剂PET/CT,采用基于Deauville的IMPeTUs标准评分并计算hTepe与myPET复合评分。

主要发现

  • 队列含22男13女,平均年龄62.2±10.9岁,初诊分期19例、再分期16例。
  • FDG检出49%患者活动性疾病,灵敏度50.0%,阳性预测值100%。
  • 氟胆碱检出91%患者疾病,灵敏度94.1%,阳性预测值100%。
  • 骨髓Deauville评分中位数相似(评分3),氟胆碱高代谢灶评分中位数显著更高(4 vs 1,p<0.001)。
  • 氟胆碱摄取与骨髓浆细胞浸润中度相关,与血红蛋白及白蛋白呈负相关;FDG无一致生化关联。

关键数值与推荐

  • 诊断性能:氟胆碱灵敏度94.1%、阳性预测值100%;FDG灵敏度50.0%、阳性预测值100%。
  • 评分标准:采用基于Deauville的IMPeTUs标准,并计算探索性复合评分hTepe与myPET。

临床怎么用

  • 氟胆碱PET/CT可用于多发性骨髓瘤分期、残留病评估与治疗监测,作为反映疾病负荷的显像生物标志物。

局限性

  • 单中心回顾性设计,样本量35例,复合评分为探索性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Multiple myeloma (MM) frequently evades complete evaluation with 18 F-FDG-PET/CT due to variable hexokinase expression, leading to false-negative findings. 18 F-fluorocholine-PET/CT (FCH) targets membrane phospholipid synthesis and has been proposed as an alternative imaging strategy to address this limitation. METHODS: In this single-center retrospective study, 35 adult MM patients underwent dual-tracer PET/CT within four weeks. Lesions were scored using Deauville-based criteria (IMPeTUs), and exploratory composite scores (hTepe and myPET) were calculated. Laboratory markers, including M-protein, free light chains, and bone marrow infiltration, were collected within four weeks of imaging. RESULTS: The cohort (22 men, 13 women; mean age 62.2 ± 10.9 years) included 19 patients at initial staging and 16 at restaging. FDG detected active disease in 49% of patients, with 50.0% sensitivity and 100% positive predictive value (PPV). FCH identified disease in 91%, achieving 94.1% sensitivity and 100% PPV. Median bone marrow Deauville scores were similar (score-3), but FCH demonstrated significantly higher hypermetabolic focus scores (median 4 vs. 1; p < 0.001). FCH uptake moderately correlated with marrow plasma cell infiltration and inversely with hemoglobin and albumin, whereas FDG showed no consistent biochemical associations. CONCLUSION: FCH demonstrates superior diagnostic performance compared to FDG in MM, particularly in red marrow-rich regions. FCH more reliably reflects disease burden and aligns more closely with laboratory markers, supporting its role in staging, residual disease assessment, and treatment monitoring. Collectively, these results highlight FCH as a clinically applicable biomarker of disease burden with potential utility in routine staging and response evaluation in multiple myeloma.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kaya G, Akin S, Buyukasik Y, et al. PET in myeloma redefined: a comparative imaging study with FDG and fluorocholine PET/CT. Eur J Nucl Med Mol Imaging. 2025. PMID: 41128865. doi:10.1007/s00259-025-07624-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。